Participated · Equity · Oct 2025

Spun out of research at the Swedish University of Agricultural Sciences, Arevo formulates arginine-phosphate, a bio-based fertiliser that helps soils retain nutrients, reduces nitrogen runoff, and lowers fertiliser-related greenhouse-gas emissions. Fertilisers are responsible for roughly 5 % of global emissions, and Arevo positions its product as a scalable, low-emission alternative to conventional nitrogen fertilisers. Backed by Industrifonden, Fort Knox, Navigare Ventures, and forest-products group Stora Enso, the company is moving from pilot-scale to industrial-scale production. Recent capital will fund manufacturing scale-up, international market entry, and continued R&D. Arevo has also entered the consumer segment with a bio-based lawn fertiliser aimed at sustainability-minded homeowners. To navigate tightening EU fertiliser regulations, the firm expanded its board, adding former Swedish Green Party leader Maria Wetterstrand, Navigare Ventures CEO David Sonnek, Stora Enso deputy CEO Henrik Lenning, and Industrifonden’s Anna Haupt. No revenue or user metrics have been disclosed to date, but successive raises signal investor confidence in the company’s commercial trajectory.

Led · Series A · Aug 2024

Impactpool is an AI-enabled career platform provided by Intalma – International Talent Management that aggregates vacancies from hundreds of international organizations. It focuses on roles at UN organizations, international financial institutions, the European Union, and leading intergovernmental and non-governmental organizations. Founded in 2015 and led by CEO Magnus Bucht, Impactpool operates as a social enterprise supporting people pursuing careers in mission-driven organizations. The platform's core product is a vacancy aggregation and career-matching system powered by AI to surface relevant opportunities across the sector. The company plans to use newly raised capital to enhance its technology and expand its business reach. Impact Pool, founded in 2015, is a social enterprise that operates a career platform for people seeking careers within mission-driven organizations. The platform gathers vacancies from hundreds of international organizations worldwide, covering UN organizations, international financial institutions, the European Union and major intergovernmental and non-governmental organizations. It provides qualified and motivated individuals with career resources to grow professionally and offers organizations a source for reaching top candidates. Impact Pool is provided by Intalma – International Talent Management and was previously known as UNjobfinder. In August 2018 the company secured $820k in funding from backers including Staffan Ingeborn and Lexis Invest, alongside other new and existing investors.

Participated · Equity · Jan 2021

Future Ordering provides a cloud-based ordering platform that enables online, app, and self-ordering kiosk orders seamlessly integrated with restaurants' POS systems. The platform is deployed across 10 countries and processes millions of transactions per month, serving customers including Max Burgers and Circle K. Founded in Sweden in 2016 and based in Stockholm, the company employs about 40 people and plans to double its team within two years and open offices outside Europe. Future Ordering positions itself at the forefront of innovation and digital transformation in food & beverage, collaborating with customers to develop new capabilities. Planned R&D focuses on data and AI to enable contextual food recommendations, targeted marketing, and more efficient restaurant operations. The company says its platform helped customers remain open during the pandemic as brands accelerated digitalization.

Participated · Equity · Oct 2017

Umecrine Cognition is a portfolio company of Karolinska Development advancing golexanolone, its lead drug candidate. The company is financing the ongoing Phase 2 clinical trial of golexanolone in primary biliary cholangitis and covering working capital needs. It recently presented strong preclinical data supporting the candidate. The latest funding was implemented as a convertible loan with attached share options and totals SEK 30.4 million. Karolinska Development participates in the investor consortium and currently holds a 73% stake in Umecrine Cognition. Upon full exercise of the new and two earlier convertible loans with similar terms, Karolinska Development's holding would decrease to 62%. Umecrine Cognition is a portfolio company of Karolinska Development focused on developing the drug candidate golexanolone. The company has secured additional financing to advance a clinical Phase 2 trial of golexanolone in primary biliary cholangitis (PBC) and to fund preclinical studies in Parkinson’s disease. The financing was implemented as a convertible loan with attached share options totaling SEK 31.6 million. An investor consortium comprising Karolinska Development, AB Ility and Ribbskottet AB provided the funding, and Karolinska Development participated in the round. Karolinska Development currently owns 73% of Umecrine Cognition; upon full exercise of the attached share options its holding would decrease to 63%. Karolinska Development expects the dilutive effect of the transaction to produce a negative earnings effect of SEK 19.7 million in Q1 2023. Company management highlights the treatment’s potential in both PBC and Parkinson’s disease, areas described as lacking adequate treatments. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. Its most advanced candidate, golexanolone, is being evaluated in patients with primary biliary cholangitis (PBC) and hepatic encephalopathy (HE). Previous clinical and preclinical studies indicate golexanolone can counteract inappropriate suppression of brain activity that produces fatigue, difficulty concentrating and impaired motor function. The company has secured SEK 41 million in funding implemented as a convertible loan with attached share options to enable the start of a Phase 2 study of golexanolone in PBC. Karolinska Development is investing SEK 15 million as part of an investor consortium that includes AB Ility. Karolinska Development currently owns 73% of Umecrine Cognition; upon full exercise of the share options its holding would decrease to 65%. Karolinska Development expects a negative earnings effect of SEK 49 million (7.7%) in Q3 2022 due to the dilutive transaction. Umecrine Cognition is developing golexanolone, a drug candidate with a novel mechanism of action that attenuates incorrect activation of the GABAA receptor in the brain. Positive phase 2 results in hepatic encephalopathy were published in the Journal of Hepatology, supporting initiation of late clinical‑phase studies and expansion into other disease areas. The company carried out a directed new share issue of SEK 35.1 million to broaden its ownership base and finance continued clinical development and IPO preparatory activities. Concurrently, Karolinska Development converted SEK 66.9 million of loans into shares at the same subscription price as the new issue. Following the transactions Karolinska Development’s ownership in Umecrine Cognition increased to 72.59 percent. Vator Securities acted as financial advisor in connection with the share issue, and the company planned an IPO on Nasdaq First Growth Market in Q4 2021. Umecrine Cognition is developing GR3027, a GABAA-receptor modulating steroid antagonist intended to treat sleep disorders. The company plans an explorative phase 2a study of GR3027 for idiopathic hypersomnia funded by the recent financing. GR3027 is also being developed as a potential treatment for hepatic encephalopathy and recently showed good results in a phase 1b trial. The phase 1b study reported that GR3027 was well tolerated, had no dose-limiting side effects, and exhibited a favorable pharmacokinetic profile. Idiopathic hypersomnia currently has no effective treatment, making the new indication potentially significant. To support the expanded clinical development, Umecrine Cognition closed a financing round raising SEK 20 million.